2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12C.06 Clinical Characteristics and Outcomes in Patients with Leptomeningeal Disease (LMD) from Non-Small Cell Lung Cancer

P3.12C.06 Clinical Characteristics and Outcomes in Patients with Leptomeningeal Disease (LMD) from Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study conducted at the University of Texas MD Anderson Cancer Center focuses on leptomeningeal disease (LMD), a severe complication in 3-5% of advanced non-small cell lung cancer (NSCLC) patients, who typically have a poor prognosis with an overall survival (OS) of less than 6 months. The study retrospectively analyzed clinical data from 124 patients diagnosed with NSCLC and confirmed LMD, examining treatment outcomes and clinical characteristics to identify factors associated with improved leptomeningeal overall survival (LMOS).<br /><br />The findings reveal that treatment with CNS-penetrant tyrosine kinase inhibitors (TKIs) is significantly associated with improved LMOS. These include third-generation EGFR TKIs such as Osimertinib, along with 2nd and 3rd generation ALK TKIs, RET inhibitors, and METex14 inhibitors. In contrast, the use of immunotherapy and CNS radiation did not show significant improvements in LMOS, although intrathecal therapy showed a trend towards better survival outcomes.<br /><br />The cohort had a median age of 61 years, with a slight majority being female. The study encompassed diverse racial backgrounds, notably Caucasian and Asian participants, and the majority were diagnosed with adenocarcinoma. A significant portion had prior brain metastases, and the most commonly observed clinical stratifier was a smoking history, which negatively affected survival. The study used both univariate and multivariate analyses to determine the impact of these factors on survival.<br /><br />The research highlights the importance of CNS-penetrant therapies in extending survival in patients with NSCLC and LMD and underscores the need for further studies to fully understand the benefits of evolving treatment strategies for this patient demographic.

Asset Subtitle

Kelsey Pan

Meta Tag

Speaker Kelsey Pan

Topic Metastatic NSCLC – Targeted Therapy

Keywords

leptomeningeal disease

non-small cell lung cancer

CNS-penetrant tyrosine kinase inhibitors

EGFR TKIs

ALK TKIs

RET inhibitors

METex14 inhibitors

intrathecal therapy

brain metastases

smoking history